Bio Pharma Dive

MAY 4, 2022

revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.

Sales 154

Sales Antibody Marketing Drugs 154

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

pharmaphorum

OCTOBER 6, 2022

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4

Sales 98

Sales Drugs Branding Antibody 98

XTalks

JANUARY 3, 2025

The global market for eye drugs continues to grow as vision-related conditions, particularly among aging populations, drive demand for innovative therapies. In this blog, we delve into the recent sales data to highlight the top three best-selling eye drugs in 2023. Fourth-quarter US net sales of Eylea in 2023 totaled $1.34

Sales 85

Sales FDA Approval Drugs Medicine 85

Pharmaceutical Technology

NOVEMBER 21, 2022

Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs. As per the partnership, Nona will offer Dragonfly access to its HCAb technologies and antibody generation services for the targets chosen by the latter.

Antibody 130

Antibody Drugs Engineer Sales 130

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Protein 124

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. The agreements also include the manufacturing and commercialisation of the two assets, including DB-1303 and DB-1311, across the globe.

Development 246

Development Sales Antibody Manufacturing 246

Fierce Pharma

JANUARY 31, 2024

AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.<

Sales 81

Sales Antibody Drugs 81

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130

Fierce Pharma

MAY 6, 2024

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ADC Therapeutics provided several company updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded (..)

Sales 83

Sales Antibody Drugs 83

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. The legal dispute is centered around rival cholesterol-lowering drugs produced by the two companies, which were approved in the summer of 2015. Both drugs come with a high price tag.

Antibody 262

Antibody Drugs Protein Sales 262

Pharmaceutical Technology

JULY 8, 2022

Zynlonta is a CD19-directed antibody-drug conjugate (ADC). Sobi will also make potential regulatory and sales-based milestone payments of up to nearly $330m to ADC as well as royalty payments based on net Zynlonta sales in territories of the former.

Sales 162

Sales Antibody Marketing Drugs 162

STAT News

MARCH 13, 2023

Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43 billion. The deal helps Pfizer, flush with cash but in need of new sources of revenue due to declining sales of Covid treatments, by adding a lineup of cancer drugs called antibody-drug conjugates that work by delivering chemotherapy directly to tumors.

Drugs 105

Drugs Sales Antibody 105

BioSpace

OCTOBER 26, 2023

billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3

Sales 103

Sales Antibody Drugs 103

Fierce Pharma

JULY 25, 2024

While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of (..)

Sales 90

Sales Drugs Manufacturing Antibody 90

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

JUNE 15, 2023

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.

Antibody 130

Antibody Protein Sales Development 130

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. lenalidomide) + a steroid ± an anti-CD38 antibody. Should CAR-T cells, or antibodies be used first?

Antibody 147

Antibody Sales FDA Approval Production 147

Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Development 130

Development Antibody Pharma Production Engineer 130

pharmaphorum

JANUARY 25, 2022

The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the back of data suggesting they have are “highly unlikely” to be effective against the now-dominant Omicron variant. billion sales for its COVID-19 antibodies in the first nine months of 2021, while Regeneron booked a whopping $4.7

Antibody 98

Antibody Drugs Sales Development 98

Pharmaceutical Technology

MAY 12, 2023

On 8 May 2023, China-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration with Eisai to develop BB-1701, an antibody-drug conjugate (ADC) for multiple cancer types. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Clinical Trials 162

Clinical Trials Clinical Trials Licensing Licensing 162

Pharmaceutical Technology

MAY 19, 2023

Roche’s anti-CD20 monoclonal antibody Rituxan/MabThera (rituximab) is one of the most successful oncology drugs of all time. Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014.

Sales 147

Sales Production Marketing FDA Approval 147

Pharmaceutical Technology

MAY 5, 2023

In the US, Eylea’s (aflibercept) net product sales decreased by 6% to $1.43bn from $1.5bn in Q1 2022 owing to a rise in sales-related deductions, partly offset by higher sales volume. Worldwide net sales of Dupixent increased by 37% to $2.49bn Q1 to Q1 2022-23.

Sales 130

Sales Antibody Production Medicine 130

pharmaphorum

DECEMBER 23, 2021

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. Novartis added inclisiran to its pipeline after buying The Medicines Company – which had licensed the drug from Alnylam – for $9.7 It has a long way to go.

Drugs 105

Drugs Sales Antibody FDA Approval 105

pharmaphorum

OCTOBER 19, 2020

Novartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering drug inclisiran – and the Swiss pharma is now a step closer to getting a return on its investment. That said, Novartis is no stranger to building a slow-starting cardiovascular drug into a blockbuster franchise.

Drugs 98

Drugs Gene Silencing Sales Antibody 98

Pharmaceutical Technology

APRIL 24, 2023

Researchers may develop nanodrugs due to their smaller surface area to allows drugs to dissolve faster, or nanoparticles may encapsulate drugs, so they last longer in the body. Since then, the drug has been used off-label in breast cancer and other types of cancer. He says, “It gave a new lease [on] life to the field”.

Drug Delivery 147

Drug Delivery Vaccine Vaccination Research 147

pharmaphorum

NOVEMBER 21, 2022

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D. . It also has an option on global marketing rights to the drug.

Drugs 116

Drugs Insulin FDA Approval Sales 116

XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Antibody Sales Protein 66

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The FDA also awarded priority review for Eli Lilly’s donanemab, a monoclonal antibody for Alzheimer’s disease, in August 2022, and the company expects approval by February 2023. and 10%, respectively.

Marketing 130

Marketing Vaccine Vaccination Sales 130

pharmaphorum

JULY 29, 2021

The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, preparing for a market showdown with Bayer and Regeneron’s market-leading Eylea. It could also reduce the cost and administrative burden for healthcare systems if the drug is priced keenly. billion for Novartis.

Drugs 98

Drugs Sales Marketing Antibody 98

Fierce Pharma

MARCH 7, 2024

GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.

Antibody 91

Antibody Sales Trials Medicine 91

Pharmaceutical Technology

APRIL 13, 2023

Biogen opted into Denali’s Antibody Transport Vehicle (ATV): Amyloid beta programme (ATV: Aβ) as part of a binding agreement signed by the companies in 2020, to co-develop and co-commercialise Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

pharmaphorum

AUGUST 21, 2020

Doctors have called for rules to be tightened on coronavirus antibody tests in the UK amid fears that false readings could put the public at risk. It’s not even known for sure that having antibodies against the SARS-CoV-2 coronavirus confers immunity. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Doctor 76

Doctor Doctors Antibody Marketing 76

XTalks

DECEMBER 20, 2024

The US Food and Drug Administration (FDA) has approved Celltrions Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for the treatment of several immune-mediated diseases. Steqeyma joins the growing list of Stelara biosimilars and is the seventh to gain FDA approval, following Biocon Biologics Yesintek (ustekinumab-kfce).

FDA Approval 52

FDA Approval Immune Response Antibody Marketing 52

pharmaphorum

OCTOBER 24, 2022

Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling injectable rivals. The post Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial appeared first on.

Trials 81

Trials Drugs Antibody Sales 81